Definitive Contract 75N93024C00043

Award Date 9/1/24
Potential Completion Date 4/14/25
Potential Value $300K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Milpitas, CA 95035, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
<p>The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Aldatu Biosciences, Inc. for the development of a rapid, sensitive, and cost-effective method to detect drug-resistant HIV minority variants. The contract, valued at $298,690.00, is a Definitive Contract with a Firm Fixed Price pricing type. The contract has an ultimate completion date of December 14, 2017.</p>
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,206.00 firm fixed-price Small Business Innovation Research (SBIR) Phase I contract to Intuitive Biosciences Inc., a small disadvantaged business, to develop &quot;THE EV-HIV ASSAY, A POINT-OF-CARE LATERAL FLOW IMMUNOASSAY TO ACCURATELY IDENTIFY HIV INFECTION FROM BLOOD-BASED EXTRACELLULAR VESICLES.&quot; This contract is linked to a broader SBIR solicitation issued by the NIAID and Centers for Disease Control...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, has awarded a $299,968 Small Business Innovation Research (SBIR) Phase I contract to Vitruvian Bio, LLC, a small disadvantaged and woman-owned business. The contract is for the development of an &quot;Electrochemical Self-Monitoring Device for Rapid Nucleic Acid Based Testing of HIV-1&quot;. This specialized medical research and diagnostic technology...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Definitive Contract to Ai Biosciences, Inc., a minority-owned, self-certified small disadvantaged business, for the development of a low-cost, automated, and rapid home HIV viral load test. The award, which is part of the Small Business Innovation Research (SBIR) Program Phase I, has a potential value of $294,538.00 and a completion date of...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services, to Accelevir Diagnostics LLC, a woman-owned small business. The contract, valued at $299,975.00, is for the company to adapt its Intact Proviral DNA Assay (IPDA) to measure latent HIV-1 for individuals with the CRF-1_AE genetic subtype of the virus. This contract is part of NIAID's Small Business Innovation Research (SBIR)...
This is a $300,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Luna Labs USA LLC, a small business manufacturer based in Charlottesville, Virginia. The contract is for the development of a rapid nucleic acid test for HIV-1, with a period of performance through April 2025. The contract includes two subcontractors - Gener8, LLC, a medical device manufacturer providing engineering services...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, awarded a $224,751 firm-fixed-price contract to Glucosentient Inc., a small business, for the development of a &quot;TELE-MONITORING FOR INFECTIOUS DISEASES: A REMOTE SYSTEM FOR ASSESSING PATIENT PARAMETERS AND SPECIMEN ANALYSIS.&quot; The contract, which has an ultimate completion date of August 29, 2017, was set aside for small businesses. Glucosentient, a...
This federal contract award, valued at $299,659.00, was granted to Big Eye Diagnostics Inc., a small business manufacturer of goods, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The contract is part of the Small Business Innovation Research (SBIR) program and is a Definitive Contract with a Firm Fixed Price pricing type. The contract is for the development of an &quot;easy-to-use, low-cost triplex RDT for the...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Darwin Biosciences, Inc., a minority-owned, woman-owned small business based in Broomfield, Colorado. The $299,408 firm-fixed-price contract is for the development of rapid diagnostic assays to aid in the self-monitoring of acute or rebound HIV-1 infection. The contract has an ultimate completion date of April 14, 2025. As an SBIR Phase I award,...
The Department of Health and Human Services, National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Fluid Discovery, Inc., a for-profit small business, to develop &quot;Multiplexed Droplet Digital Nucleic Acid Amplification Technologies for HIV Diagnosis.&quot; The $299,903 firm-fixed-price contract, which runs through July 31, 2024, supports research and development of innovative...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,576 Small Business Innovation Research (SBIR) Phase I contract to Gate Scientific, Inc., a small business manufacturer located in Milpitas, California. The contract is for the development of a disposal point-of-care HIV nucleic acid test. This award is a Firm Fixed Price Definitive Contract and is set aside for small businesses. Gate Scientific, Inc. has demonstrated expertise in developing advanced molecular diagnostic and testing technologies, including point-of-care diagnostic tests and molecular detection devices for various federal agencies such as the Department of Homeland Security.

Generated 6/26/25, 10:12 AM